Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking ...

Most of the disease-causing bacteria secrete matrix-like layers around themselves called biofilms. These biofilms act as ...

Consisting of five separate booklets, the World Drug Report 2021 provides an in-depth analysis of the global drug markets and paints a comprehensive picture of the measurable effects and potential ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...